Samsung Biologics signs $1.24bn manufacturing deal with Asian pharma company
Samsung Biologics, a leading contract development and manufacturing organization (CDMO), has secured a contract manufacturing deal valued at $1.24bn with an Asia-based pharmaceutical company.